Billionaire Masayoshi Son, founder and CEO of Japanese multinational investment company SoftBank Group, is one of the richest ...

The Japanese investment holding company SoftBank Group ( OTCPK:SFTBY) purchased two new stakes: 20.45M shares in Pacific Biosciences of California ( PACB ), and 14.66M shares in Recursion ...

As a telecom and technology investment company, SoftBank Group represents a unique investment opportunity. The current portfolio is a mix of internet and technology investments with a stake in a ...

SoftBank just took a $2.4 billion hit in its fiscal third quarter, sinking into losses as the Japanese tech giant prepares to ...

DeepSeek may spark a “near-term market correction” for SoftBank and other AI stocks, said chief executive officer Yun Jung-in ...

For SoftBank Group Corp. investors looking for the stock to climb back to all-time highs on a revival of the artificial ...

Japanese investor SoftBank Group Corp’s tech-focused Vision funds reported an investment loss of $2.3 billion (352.7 billion ...

SoftBank posts a $2.4B Q4 loss, hit by Vision Fund declines despite a major AI push. The firm nears a $40B OpenAI deal, aiming to offset investment struggles.

While market sentiments among SoftBank investors remain pessimistic due to the emergence of more low-cost alternatives from China, there is still hope.

Shares of Recursion Pharmaceuticals closed 23.88% higher on Friday, marking their best single-day gain in nearly two years.